What Is Tysabri and PML? A Clear Explanation
Latest update (2026-07)
- Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Awareness to Targeted Risk Assessment
If you or a loved one has been diagnosed with progressive multifocal leukoencephalopathy (PML) after taking Tysabri, you likely have urgent questions about what this condition means and what comes next. Decades of pharmacovigilance and clinical research have established PML as a rare but serious adverse event associated with certain biologic therapies, including natalizumab. This page provides a straightforward overview of PML, its connection to Tysabri, and the essential facts every patient should know.
Tysabri and the Risk of Progressive Multifocal Leukoencephalopathy
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration has assigned a boxed warning to Tysabri highlighting this risk, which is the strongest safety alert for a prescription drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors increase the likelihood of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefits when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which mandates regular monitoring and reporting (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals must evaluate patients three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). They must also determine every six months whether patients should continue treatment and submit status reports to Biogen, the manufacturer (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Cases of PML, hospitalizations due to opportunistic infections, and deaths must be reported to Biogen as soon as possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Clinical Presentation and Mechanism of PML
Clinical presentation of PML typically includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis relies on brain MRI and detection of JCV DNA in cerebrospinal fluid. The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can allow latent JCV to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and neuronal damage. For patients in Texas who have developed PML after Tysabri exposure, settlement considerations may arise from allegations that the manufacturer failed to provide adequate warnings about the risk. The boxed warning and TOUCH program were implemented after initial reports of PML, but some patients may have been treated before these measures were fully in place or may not have received sufficient information about risk factors.
Statute of Limitations for Tysabri Claims in Texas
The statute of limitations for filing a product liability claim in Texas generally is two years from the date the injury was discovered or should have been discovered through reasonable diligence. This timeline is critical because PML can have a delayed onset, with symptoms appearing months to years after starting Tysabri. The latency between exposure and documented harm can complicate the determination of when the statute begins to run. Courts may consider the date of diagnosis or the date when the patient first experienced symptoms that could be linked to Tysabri. Patients and their families should be aware that the adequacy of warnings is a central issue in any settlement. The FDA-approved labeling clearly states that Tysabri increases PML risk and identifies specific risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, if a patient was not informed about these risks or if the monitoring requirements were not followed, there may be grounds for a claim. Settlement amounts can vary based on the severity of disability, medical expenses, lost income, and pain and suffering. Given the severe outcomes associated with PML, including death or permanent disability, settlements may be substantial.
Legal Considerations and Next Steps
In summary, Tysabri-associated PML is a serious adverse event with known risk factors and a mandated monitoring program. For Texas patients, the statute of limitations requires prompt action after diagnosis. Legal counsel experienced in pharmaceutical litigation should be consulted to evaluate the specific circumstances, including the timeline of exposure, diagnosis, and any alleged failure to warn. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for a Tysabri PML lawsuit in Texas?
In Texas, the statute of limitations for product liability claims is generally two years from the date the injury was discovered or should have been discovered. Because PML symptoms can appear months to years after starting Tysabri, the clock may start at diagnosis or when symptoms first become linked to the drug. It is crucial to consult an attorney promptly to avoid missing the deadline.
What are the risk factors for developing PML while on Tysabri?
Three established risk factors increase PML risk: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the FDA boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
- Is Progressive Multifocal Leukoencephalopathy from Tysabri permanent
- Long term outcome of Progressive Multifocal Leukoencephalopathy after Tysabri
- Treatment for severe Progressive Multifocal Leukoencephalopathy after Tysabri
- Statute of limitations for Tysabri in Ohio
- Tysabri Progressive Multifocal Leukoencephalopathy lawsuit settlement criteria
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.